In order to maintain the momentum, OSTP Director John Holdren today is requesting that every covered department and agency provide its draft scientific integritypolicy within 90 days from today.
Under the Application IntegrityPolicy, the most recent action, the FDA has stopped all scientific review of any new or pending drug approval applications containing data from the Paonta Sahib plant.
In its second action in six months against Ranbaxy's Paonta Sahib plant, the FDA invoked its Application IntegrityPolicy, which is usually invoked over concerns about the integrity of data in drug applications.